The Food and Drugs Administrationâ€™s Office of Generic Drugs (OGD) is a division under the Center for Drug Evaluation in Research (CDER) that focuses on the approval and facilitation of generic drugs. The purpose of the OGD is to ensure that the drug products distributed in the United States (US) are of high quality, and are safe and effective to use. The OGD ensures that the generic drugs distributed in the US have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug.
Responsibilities of the OGD
To approve generic drugs by reviewing abbreviated new drug applications (ANDAs)
To act as the central point of communication between the FDA and the applicants
To guide and oversee the Regulatory scenarios of generic drugs
To ensure that the Generic Drug User Fee Amendments commitments are fulfilled
To conduct research as per the GDUFA Regulatory Science Plan
Investigate adverse event reports or similar reports related to generic drugs by interacting with various healthcare providers
Offices Under the OGD
Office of Generic Drugs Immediate Office
Office of Bioequivalence
Office of Generic Drug Policy
Office of Regulatory Operations
Office of Research and Standards
The review process of the OGD
Facilitating approval of drugs by managing the Regulatory process
Initiating generic drugs research
Gathering and publishing the data & reports on the development & review of generic drugs
Providing educational material and related information on generic drugs
The OGD was set up by the FDA to ensure the safety and efficacy of the generic drugs distributed in the US. Are you aligned with the regulations of OGD? Reach out to Freyr for compliance. email@example.com.
About the Author:
This article talks about the effective regulatory strategies for Medical Devices registration across the globe.